中文名：A922500,DGAT-1抑制劑

英文名：A922500

純度：≥98%

貨號：A129800

Cas號：959122-11-3

存儲溫度：-20°C儲存

運輸條件：超低溫運輸

產(chǎn)品介紹：

DGAT-1 inhibitor A?922500 (A-922500) reduces serum triglyceride levels from baseline at all doses tested; however, this is only statistically significant at the 3?mg/kg dose, which lowers serum triglycerides by 53%. Similarly, the 3?mg/kg dose of A?922500 significantly reduces serum FFA concentrations by 55% and total cholesterol by 25%. DGAT-1 inhibition has no significant effect on body weight at any dose tested. Although A?922500 dpes not significantly affect LDL-cholesterol or HDL-cholesterol individually, the serum LDL/HDL-cholesterol ratio is significantly improved by A?922500 at 0.3 and 3?mg/kg. Similar to the dyslipidemic hamster, treatment with 3?mg/kg A?922500 significantly reduces serum triglyceride concentrations (39%). FFA levels significantly increase over the 14-day period in vehicle-treated animals. This increase is inhibited in a?dose-dependent manner by A?922500 such that FFA concentrations are 32% lower after 14 days of treatment with the DGAT-1 inhibitor at 3?mg/kg, compared with the vehicle group (p < 0.05). HDL-cholesterol is significantly increased from baseline levels by A?922500 at 0.3 and 3?mg/kg; however, this is only significantly increased compared with vehicle at the 3?mg/kg dose. Body weight significantly increases over the 2-week period in vehicle-treated rats, and this is not affected by A?922500. LDL-cholesterol is significantly reduced in the vehicle treated group. DGAT-1 inhibition does not further reduce LDL-cholesterol and has no effect on total cholesterol.

產(chǎn)品用途：

A922500 has been used in the inhibition of diacylglycerol acyltransferase (DGAT) in epithelial human breast cancer cell line (MDA-MB-231), digitonin-permeabilized human cancer cells, human myotubes and macrophages.

查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對應頁面：https://www.aladdin-e.com/zh_cn/A129800.html